Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00016
|
|||||
| Drug Name |
Meperidine
|
|||||
| Synonyms |
1-Methyl-4-phenyl-4-piperidinecarboxylic acid ethyl ester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester; 1-Methyl-4-phenyl-piperidin-4-carbon-saeure-aethylester [German]; 1-Methyl-4-phenylisonipecotic acid, ethyl ester;1-Methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester; 4-Carbethoxy-1-methyl-4-phenylpiperidine; 4-Piperidinecarboxylic acid, 1-methyl-4-phenyl-, ethyl ester; Demarol; Demerol; Demerol (TN); Dolcontral; Dolosal; Dolsin; Ethyl 1-methyl-4-phenylisonipecotate; Ethyl 1-methyl-4-phenylpiperidine-4-carboxylate; Isonipecain; Isonipecaine; Isonipecotic acid, 1-methyl-4-phenyl-, ethyl ester; Lidol; Lydol; Meperidine solution; Meperidol; Methyl phenylpiperidine carbonic acid ethyl ester; N-Methyl-4-phenyl-4-carbethoxypiperidine; Nemerol; Operidine EPJ I; Operidine EPJ-I; Pethanol; Pethidin; Pethidine; Pethidine (INN); Pethidine DBL; Pethidine DBL (TN); Pethidineter; Pethidinum; Pethidinum [INN-Latin]; Petidina; Petidina [INN-Spanish]; Petydyna; Petydyna [Polish]; Phetidine; Piperosal; Pipersal; YIsonipecotic acid, 1-methyl-4-phenyl-, ethyl ester (8CI)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Moderate to severe pain [ICD11:MG30-MG3Z] | Approved | [1] | |||
| Therapeutic Class |
Anesthetics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C15H21NO2
|
|||||
| Canonical SMILES |
CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2
|
|||||
| InChI |
InChI=1S/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3
|
|||||
| InChIKey |
XADCESSVHJOZHK-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 57-42-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 247.33 | Topological Polar Surface Area | 29.5 | ||
| Heavy Atom Count | 18 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 3 | |||
| XLogP |
2.5
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103184537
,103936336
,104305308
,10527888
,11336158
,11361397
,11462369
,126407782
,129659418
,134337544
,134970866
,137003750
,140053016
,14823367
,160963800
,175267872
,177513108
,178103795
,179148680
,184546706
,223440287
,224511988
,226413511
,241102133
,24882043
,249933926
,29223169
,4359668
,46506899
,47736577
,48416212
,49986147
,50185474
,53789706
,57322120
,57651808
,7978480
,8152545
,841258
,85209612
,9338
,96025030
|
|||||
| ChEBI ID |
ChEBI:6754
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Meperidine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs. Bioorg Med Chem Lett. 2008 Jun 15;18(12):3638-40. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.